Humana (NYSE:HUM) Releases FY 2025 Earnings Guidance

Key Points

• Humana provided FY 2025 earnings per share guidance of $17.00 and revenue guidance of $128.0 billion.
• The consensus rating for Humana's stock is "Hold" with a target price of $282.43, reflecting mixed sentiments among analysts.
• The company's recent performance showed an earnings per share of $11.58 for the last quarter, exceeding estimates and representing an 8.4% increase in revenue year-over-year.

Humana (NYSE:HUM - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 17.000- for the period. The company issued revenue guidance of $128.0 billion-.

Analyst Ratings Changes

Several brokerages have recently commented on HUM. Barclays set a $275.00 target price on shares of Humana and gave the company an "equal weight" rating in a research report on Thursday. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Robert W. Baird lowered their price objective on shares of Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research report on Friday, July 25th. Wall Street Zen upgraded shares of Humana from a "hold" rating to a "buy" rating in a research report on Sunday, July 20th. Finally, Oppenheimer upped their price objective on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Sixteen equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, Humana has an average rating of "Hold" and a consensus target price of $281.62.

Humana Stock Down 1.1%

Shares of Humana stock traded down $2.68 during trading on Friday, hitting $247.19. 1,756,006 shares of the stock traded hands, compared to its average volume of 1,854,830. The firm has a market cap of $29.73 billion, a P/E ratio of 18.97, a price-to-earnings-growth ratio of 1.66 and a beta of 0.44. The company has a current ratio of 1.95, a quick ratio of 1.91 and a debt-to-equity ratio of 0.69. Humana has a 52-week low of $206.87 and a 52-week high of $382.72. The stock's fifty day simple moving average is $234.64 and its 200 day simple moving average is $255.48.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the previous year, the business earned $6.96 EPS. Humana's revenue for the quarter was up 9.6% compared to the same quarter last year. On average, equities analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Humana stock. Revolve Wealth Partners LLC bought a new position in Humana Inc. (NYSE:HUM - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 798 shares of the insurance provider's stock, valued at approximately $202,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.